

# Abstract Submission Guidelines

## Submitted Papers

No individual can be first author on more than one abstract. If no author on the abstract is a member, please provide the sponsor's name and e-mail address. **Fellows, Regular, or Corporate Members** can sponsor an unlimited number of abstracts. If they are not an author on the abstract, the sponsor's name and e-mail address must be entered. **Associate Members** cannot serve as sponsor on abstracts on which they are not listed as an author. **Members-In-Training** can submit one abstract on which they are first author but cannot sponsor any other abstracts. Should you need a list of members, please contact Neico Smith (neicosmith078@gmail.com) at the Executive Office of CPDD. You need to get permission from the potential sponsor before listing him/her, and you should provide a copy of the abstract to the sponsor. There is a 300 word limit for the text of the abstract.

## Subject Matter

Papers can be on any aspect of drug use disorder or addiction or on the actions of drugs of abuse. They should contribute to our knowledge of the agents involved in drug use disorder, including their molecular biology, chemistry, pharmacological action, biological disposition, abuse potential, safety or clinical usefulness. Contributions concerning research on neurobiology, epidemiology, prevention, public health aspects, or management and treatment of drug dependence are also encouraged.

## Procedures for Submission

There are four categories of abstract submissions: **Original Research, Program Descriptions, Theoretical/Commentary, and Literature Review**. All categories **must** include an Aim, a Conclusion and a "Supported by" statement (i.e., funding). Original Research must include Methods and Results sections. These sections are optional for the other categories. Details of each category are provided below.

**Original Research** includes all prospective and retrospective studies that involve testing a hypothesis by collecting and analyzing data. Abstracts of basic research or clinical studies must specify the following: hypothesis, species, number of subjects, procedures, statistical analyses, results (including specific, numerical statistical outcomes like means, p values or odds ratios), and importance of findings (conclusions). Scholarly historical or sociological reports must specify hypothesis, procedures, analyses, results, and a concluding statement describing the implications of the study. Please note that results must be explicitly described in the abstract, and that abstracts reporting no results will likely be rejected. Recently

completed studies, as yet unpublished, are preferred and any in press work must have a publication date after July 1, 2019.

**Program Descriptions** are reserved for non-experimental abstracts that simply provide a narrative of a research program or a theme that is being pursued. No data are required and the abstract can discuss potential plans for pursuing new research directions.

**Theoretical/Commentary** abstracts can be about any topic related to drug abuse including (but not limited to) policy, trends in the field, treatment strategies, mechanisms of action, and methodological issues. No data are required.

**Literature Review** abstracts should provide a scholarly discussion of a specific topic via a review of the current literature. Critical review abstracts need not have data per se but will need to have a concluding statement about the authors' findings.

All submissions will be peer-reviewed, and time, space, and programmatic needs will be considered in decisions of acceptance or rejection, and in assignment to oral or poster sessions. First authors will receive e-mail notification of acceptance with the date and time of presentation. No individual can be first author on more than one abstract. Abstracts will be available for viewing and downloading at [cpdd.org](http://cpdd.org) before the meeting.

The abstract fee of \$50.00 is payable by credit card. Abstracts submitted for oral or poster sessions must be entered by December 3, 2018. Please read the abstract guidelines and follow the instructions carefully. Failure to follow the instructions will result in rejection of your abstract.